Unlocking the Potential of CCDC32: A Promising Drug Target and Biomarker

Target Name: CCDC32

NCBI ID: G90416

CCDC32

Unlocking the Potential of CCDC32: A Promising Drug Target and Biomarker

Introduction

CDC32 (Uncharacterized protein C15orf57) is a protein that has garnered significant attention in the scientific community due to its unique structure and biofunctional properties. CDC32 is a 15kDa hydrophobic protein, which means it has a hydrophobic domain and is capable of forming a monomeric state in the absence of any ligand. Its unique features make it an attractive candidate for drug development as well as a potential biomarker for various diseases.

CDC32's Biofunctional Properties

CDC32 has been shown to have various biofunctional properties that make it an attractive candidate for drug development. One of its most notable features is its ability to form a monomeric state in the absence of any ligand. This property, known as its \"drug- like\" property, allows the protein to form a stable interface with various ligands, such as small molecules, peptides, and even viruses. This stability has been shown to enhance the protein's stability and enhance its ability to interact with other proteins, making it an ideal candidate for drug development.

Another noteworthy property of CDC32 is its ability to self-assemble into distinct cellular localizations. This property, known as its \"self-assembly\" property, allows the protein to form local domains within cells and to regulate the formation of these domains. This localization of the protein has been shown to play a role in its various functions, including cell signaling, tissue engineering, and drug delivery.

CDC32's Potential Applications

CDC32's unique properties make it an attractive candidate for drug development and as a biomarker for various diseases. One of the most promising applications of CDC32 is its potential as a drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

For instance, CDC32 has been shown to play a role in the regulation of cell signaling pathways, including the TGF-β pathway. This pathway is involved in various cellular processes, including cell growth, differentiation, and survival. Studies have shown that CDC32 can inhibit the activity of the TGF-β pathway, which may lead to the inhibition of cell signaling and the progression of various diseases. This property makes CDC32 an attractive candidate for the treatment of cancer, neurodegenerative diseases, and autoimmune diseases.

Another promising application of CDC32 is its potential as a biomarker for various diseases. Its unique properties make it capable of forming distinct cellular localizations, which can be used as biomarkers for diseases. For instance, CDC32 has been shown to form distinct localizations in the brains of individuals with Alzheimer's disease, which may indicate the presence of the protein in the brains and the progression of the disease. This property makes CDC32 an attractive candidate for the development of diagnostic tools for Alzheimer's disease and other neurodegenerative diseases.

CDC32's Potential Therapeutic Applications

CDC32's unique properties make it an attractive candidate for the development of various therapeutic applications. One of the most promising therapeutic applications of CDC32 is its potential as a monoclonal antibody (mAb) targeting small molecules. Monoclonal antibodies are laboratory-produced proteins that are capable of recognizing and binding to specific antigens with high sensitivity and specificity.

Studies have shown that mAbs targeting CDC32 have the potential to treat various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. For instance, a study by the National Cancer Institute found that mAbs targeting CDC32 have the potential to treat various diseases.

Protein Name: Coiled-coil Domain Containing 32

Functions: Has a role in ciliogenesis (By similarity). Required for proper cephalic and left/right axis development (PubMed:32307552)

The "CCDC32 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC32 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets